duchenne muscular dystrophy and glutathione Circulating Nrf2, Glutathione, Malondialdehyde Correlate with Disease Severity in Drug Discovery of Therapies for

Together, they form a potent combination that may offer enhanced benefits over existing therapies

Disclosure of interest: Xiaoqing Jiang, Zixiao Li, Yongjun Wang:nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P413 - ESOC25-196 INVESTIGATING CARDIOVASCULAR RISK AS A MODERATOR OF THE RELATIONSHIP BETWEEN BLOOD-BASED DEMENTIA BIOMARKERS AND COGNITIVE IMPAIRMENT A CROSS-SECTIONAL ANALYSIS OF DATA FROM THE BIO-HERMES STUDY Angelina Kancheva 1 , Donald Lyall 2 , Terence J Quinn 3 1 School of Cardiovascular & Metabolic Health, University of Glasgow, University of Edinburgh, Glasgow, United Kingdom, 2 School of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom, 3 School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, United Kingdom Background and Aims: Blood-based biomarkers may enhance diagnosis and prognosis of Alzheimers disease (AD) and other dementias

It may also have benefits on the brain-gut axis

Our policy mandates a medical consultation and recommendation from a licensed provider to develop a peptide therapy treatment plan